CN104968685A - 异源二聚免疫球蛋白的纯化 - Google Patents

异源二聚免疫球蛋白的纯化 Download PDF

Info

Publication number
CN104968685A
CN104968685A CN201380061419.1A CN201380061419A CN104968685A CN 104968685 A CN104968685 A CN 104968685A CN 201380061419 A CN201380061419 A CN 201380061419A CN 104968685 A CN104968685 A CN 104968685A
Authority
CN
China
Prior art keywords
immunoglobulin
fragment
district
constant region
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380061419.1A
Other languages
English (en)
Chinese (zh)
Inventor
斯坦尼斯拉斯·布兰
法布里齐奥·康珀
罗曼·奥利耶
保罗·瓦斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichnos Sciences SA
Original Assignee
Glenmark Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals SA filed Critical Glenmark Pharmaceuticals SA
Publication of CN104968685A publication Critical patent/CN104968685A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380061419.1A 2012-09-25 2013-09-25 异源二聚免疫球蛋白的纯化 Pending CN104968685A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705278P 2012-09-25 2012-09-25
US61/705,278 2012-09-25
PCT/EP2013/069989 WO2014049003A1 (en) 2012-09-25 2013-09-25 Purification of hetero-dimeric immunoglobulins

Publications (1)

Publication Number Publication Date
CN104968685A true CN104968685A (zh) 2015-10-07

Family

ID=49237223

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380061419.1A Pending CN104968685A (zh) 2012-09-25 2013-09-25 异源二聚免疫球蛋白的纯化

Country Status (11)

Country Link
US (2) US20150239991A1 (enExample)
EP (2) EP2900696A1 (enExample)
JP (5) JP2015529236A (enExample)
KR (1) KR20150076172A (enExample)
CN (1) CN104968685A (enExample)
AU (2) AU2013322710A1 (enExample)
CA (2) CA3061557A1 (enExample)
HK (1) HK1215950A1 (enExample)
IL (2) IL237872B (enExample)
IN (1) IN2015MN00139A (enExample)
WO (1) WO2014049003A1 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071635A (zh) * 2016-05-02 2018-12-21 豪夫迈·罗氏有限公司 Contorsbody－单链靶标结合物
CN109790215A (zh) * 2016-09-29 2019-05-21 北京韩美药品有限公司 异源二聚体免疫球蛋白构建体和其制备方法
CN112262154A (zh) * 2018-04-26 2021-01-22 利摩日大学 人类重链伪γ基因编码的新型IGG5类重组免疫球蛋白
US11129905B2 (en) 2015-10-25 2021-09-28 Sanofi Bivalent, bispecific binding proteins for prevention or treatment of HIV infection
US11192960B2 (en) 2016-04-13 2021-12-07 Sanofi Trispecific and/or trivalent binding proteins
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CN116096758A (zh) * 2020-05-01 2023-05-09 诺华股份有限公司 工程化免疫球蛋白
US11932704B2 (en) 2016-04-13 2024-03-19 Sanofi Trispecific and/or trivalent binding proteins
WO2025087386A1 (zh) * 2023-10-25 2025-05-01 正大天晴药业集团南京顺欣制药有限公司 抗her2抗体药物偶联物治疗乳腺癌的用途

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
RU2013110875A (ru) 2010-08-24 2014-09-27 Ф.Хоффманн-Ля Рош Аг БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
JP5764677B2 (ja) 2011-02-28 2015-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗原結合タンパク質
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
EP2900696A1 (en) * 2012-09-25 2015-08-05 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
EP3628685A1 (en) 2013-04-29 2020-04-01 F. Hoffmann-La Roche AG Human fcrn-binding modified antibodies and methods of use
CA2922979A1 (en) * 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
EP3066133A1 (en) * 2013-11-04 2016-09-14 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
CA2932364A1 (en) * 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
KR102497443B1 (ko) 2014-03-28 2023-02-08 젠코어 인코포레이티드 Cd38 및 cd3에 결합하는 이중특이적 항체
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
CN106573986A (zh) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
BR112017011166A2 (pt) 2014-11-26 2018-02-27 Xencor, Inc. anticorpos heterodiméricos que se ligam a cd3 e cd38
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
US20180201693A1 (en) 2015-07-09 2018-07-19 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
GB201602156D0 (en) * 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
CA3043652A1 (en) 2016-11-18 2018-05-24 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
WO2019200022A1 (en) 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
CA3104390A1 (en) * 2018-06-22 2019-12-26 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
US20210340273A1 (en) 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
WO2020076977A2 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
EP3864049A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CA3115082A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
BR112021012337A2 (pt) 2018-12-24 2021-09-14 Sanofi Proteínas de ligação multiespecíficas baseadas em pseudofab
BR112022011993A2 (pt) * 2019-12-26 2022-09-20 Abl Bio Inc Método para purificar peptídeo biologicamente ativo usando cromatografia de afinidade de proteína a
KR20220148175A (ko) 2020-01-29 2022-11-04 인히브릭스, 인크. Ｃｄ28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체
CA3198102A1 (en) 2020-10-07 2022-04-14 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof
WO2022266221A1 (en) 2021-06-16 2022-12-22 Alector Llc Monovalent anti-mertk antibodies and methods of use thereof
WO2022266223A1 (en) 2021-06-16 2022-12-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
JP2023092810A (ja) * 2021-12-22 2023-07-04 国立大学法人東京農工大学 変異抗体、変異抗体の製造方法
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
CN119584978A (zh) 2022-06-07 2025-03-07 再生元制药公司 用于调节t细胞活性的多特异性分子及其用途
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
US20260070987A1 (en) * 2022-09-02 2026-03-12 Zoetis Services Llc Equine antibody mutants
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
WO2025166040A1 (en) 2024-01-31 2025-08-07 Alector Llc Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
WO2025166045A1 (en) 2024-01-31 2025-08-07 Alector Llc β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025166077A1 (en) 2024-01-31 2025-08-07 Alector Llc Compositions comprising progranulin and uses thereof
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2026013159A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors
WO2026013158A1 (en) 2024-07-10 2026-01-15 Cytospire Therapeutics Limited Antibodies binding to constant domains of gamma delta t-cell receptors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011078332A1 (ja) * 2009-12-25 2011-06-30 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
CN102171248A (zh) * 2008-10-01 2011-08-31 米克罗麦特股份公司 种间特异性PSMAxCD3双特异性单链抗体
CN102264759A (zh) * 2008-12-23 2011-11-30 弗·哈夫曼-拉罗切有限公司 与蛋白a的结合改变的免疫球蛋白变体

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE122009000068I2 (de) 1994-06-03 2011-06-16 Ascenion Gmbh Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
US8142780B2 (en) * 1998-08-20 2012-03-27 Strox Biopharmaceuticals, Llc Anti-bacterial antibodies
ES2402650T3 (es) * 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
SG173654A1 (en) 2009-02-23 2011-09-29 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to cd19 and their uses
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
PL2560993T3 (pl) * 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
US9683052B2 (en) 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
US9114516B2 (en) 2011-07-21 2015-08-25 Illinois Tool Works Inc. Portable combustion gas-powered tools with combustion chamber lockout system
HUE044633T2 (hu) * 2011-10-27 2019-11-28 Genmab As Heterodimer fehérjék elõállítása
AU2012372484A1 (en) 2012-03-06 2014-08-21 Foss Analytical Ab Method, software and graphical user interface for forming a prediction model for chemometric analysis
EP2825559B1 (en) 2012-03-13 2019-02-27 Novimmune SA Readily isolated bispecific antibodies with native immunoglobulin format
EP2900696A1 (en) * 2012-09-25 2015-08-05 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
EP3066133A1 (en) * 2013-11-04 2016-09-14 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171248A (zh) * 2008-10-01 2011-08-31 米克罗麦特股份公司 种间特异性PSMAxCD3双特异性单链抗体
CN102264759A (zh) * 2008-12-23 2011-11-30 弗·哈夫曼-拉罗切有限公司 与蛋白a的结合改变的免疫球蛋白变体
WO2011078332A1 (ja) * 2009-12-25 2011-06-30 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129905B2 (en) 2015-10-25 2021-09-28 Sanofi Bivalent, bispecific binding proteins for prevention or treatment of HIV infection
US11779651B2 (en) 2015-10-25 2023-10-10 Sanofi Bivalent, bispecific binding proteins for prevention or treatment of HIV infection
TWI750139B (zh) * 2015-10-25 2021-12-21 法商賽諾菲公司 用於預防或治療ｈｉｖ感染之三特異性及/或三價結合蛋白
TWI788286B (zh) * 2016-04-13 2023-01-01 法商賽諾菲公司 三特異性和/或三價結合蛋白
US11192960B2 (en) 2016-04-13 2021-12-07 Sanofi Trispecific and/or trivalent binding proteins
US11932704B2 (en) 2016-04-13 2024-03-19 Sanofi Trispecific and/or trivalent binding proteins
CN109071635A (zh) * 2016-05-02 2018-12-21 豪夫迈·罗氏有限公司 Contorsbody－单链靶标结合物
CN109071635B (zh) * 2016-05-02 2023-09-01 豪夫迈·罗氏有限公司 Contorsbody－单链靶标结合物
CN109790215B (zh) * 2016-09-29 2023-06-30 北京韩美药品有限公司 异源二聚体免疫球蛋白构建体和其制备方法
CN109790215A (zh) * 2016-09-29 2019-05-21 北京韩美药品有限公司 异源二聚体免疫球蛋白构建体和其制备方法
CN112262154A (zh) * 2018-04-26 2021-01-22 利摩日大学 人类重链伪γ基因编码的新型IGG5类重组免疫球蛋白
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
US12227573B2 (en) 2019-04-09 2025-02-18 Sanofi Trispecific binding proteins, methods, and uses thereof
CN116096758A (zh) * 2020-05-01 2023-05-09 诺华股份有限公司 工程化免疫球蛋白
WO2025087386A1 (zh) * 2023-10-25 2025-05-01 正大天晴药业集团南京顺欣制药有限公司 抗her2抗体药物偶联物治疗乳腺癌的用途

Also Published As

Publication number Publication date
US20200010568A1 (en) 2020-01-09
EP2900696A1 (en) 2015-08-05
WO2014049003A1 (en) 2014-04-03
CA3061557A1 (en) 2014-04-03
IL237872B (en) 2019-09-26
JP2015529236A (ja) 2015-10-05
JP6856610B2 (ja) 2021-04-07
AU2018204314A1 (en) 2018-07-05
US20150239991A1 (en) 2015-08-27
CA2886036A1 (en) 2014-04-03
IL269207B (en) 2022-02-01
JP2018104444A (ja) 2018-07-05
AU2013322710A1 (en) 2015-04-16
IN2015MN00139A (enExample) 2015-10-16
HK1215950A1 (zh) 2016-09-30
IL237872A0 (en) 2015-05-31
IL269207A (en) 2019-11-28
JP2022116326A (ja) 2022-08-09
JP2019073512A (ja) 2019-05-16
KR20150076172A (ko) 2015-07-06
JP2020105203A (ja) 2020-07-09
AU2018204314B2 (en) 2020-05-14
AU2013322710A2 (en) 2015-05-07
EP3401337A1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
JP6856610B2 (ja) ヘテロ二量体免疫グロブリンの精製
JP7403505B2 (ja) Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
AU2019257534B2 (en) Production of T cell retargeting hetero-dimeric immunoglobulins
HK1227904A (en) Production of t cell retargeting hetero-dimeric immunoglobulins
HK1227904A1 (en) Production of t cell retargeting hetero-dimeric immunoglobulins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1215950

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151007

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1215950

Country of ref document: HK